1. In Vivo
  2. >>Business Strategy

Big Pharma's Year of Big Layoffs

It has been quite a year for pharmaceutical restructuring. But where are the cuts coming from? Here's a snapshot of the 40,000 or so layoffs from the industry's big players.

When it comes to pharmaceutical restructuring, the talk in past years has mostly centered on Big Pharma’s sales force arms races, and whether or not companies like Pfizer Inc. would reduce headcount in their massive sales and marketing divisions. Going back to one day in April 2005, when Pfizer announced a plan to save $4 billion, such a move seemed inevitable. (See "Pfizer’s Analyst Day: And Now, for Its Next Trick," IN VIVO, April 2005 Also see "Pfizer's Analyst Day: And Now, For Its Next Trick" - In Vivo, 1 April, 2005..) But despite recent expected sales force cuts at Pfizer and also at AstraZeneca PLC, the industry’s collective axe has cut a broader swathe of personnel: sales, marketing, R&D, and manufacturing have all felt the pain.

Since January 2007, when Eli Lilly & Co. announced it had completed its $2.2 billion acquisition of tadalafil (Cialis)...

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.